[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477701":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":39,"responsibleParty":89,"collaborators":91,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":98,"sex":104,"minAge":105,"maxAge":23,"enrollmentInfo":106,"targetDuration":23,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":23,"overallStatus":76,"whyStopped":23,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Centre Oscar Lambret","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","Telesurveillance by a nurse",[13],"Other: Oncological Follow-up",{"label":15,"type":6,"description":16,"interventionNames":17},"Control","On-site surveillance by a hospital physician",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Oncological Follow-up","Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)",[15,9],null,[25],{"name":26,"affiliation":5,"role":27},"PENEL Nicolas, MD, PhD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},"Laurence ROTSAERT","CONTACT","0320295860 \u002F 0320295918","l-rotsaert@o-lambret.fr",{"name":35,"role":31,"phone":36,"phoneExt":37,"email":38},"Fanny BEN OUNE","0320295918","+33","f-benoune@o-lambret.fr",[40,61,75],{"facility":41,"status":42,"city":43,"state":23,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"CHU Amiens","NOT_YET_RECRUITING","Amiens","80054","France","FR",{"type":48,"coordinates":49},"Point",[50,51],2.3,49.9,{"lat":51,"lon":50},[54,57,58],{"name":55,"role":31,"phone":23,"phoneExt":23,"email":56},"Guillaume BONNET","bonnet.guillaume@chu-amiens.fr",{"name":55,"role":27,"phone":23,"phoneExt":23,"email":23},{"name":59,"role":60,"phone":23,"phoneExt":23,"email":23},"Mathieu BOONE, MD","SUB_INVESTIGATOR",{"facility":62,"status":42,"city":63,"state":23,"zip":64,"country":45,"countryCode":46,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Centre François Baclesse","Caen","14076",{"type":48,"coordinates":66},[67,68],-0.35912,49.18585,{"lat":68,"lon":67},[71,74],{"name":72,"role":31,"phone":23,"phoneExt":23,"email":73},"François GERNIER","f.gernier@baclesse.unicancer.fr",{"name":72,"role":27,"phone":23,"phoneExt":23,"email":23},{"facility":5,"status":76,"city":77,"state":23,"zip":78,"country":45,"countryCode":46,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"RECRUITING","Lille","59020",{"type":48,"coordinates":80},[81,82],3.05512,50.63391,{"lat":82,"lon":81},[85,86,87],{"name":30,"role":31,"phone":23,"phoneExt":23,"email":33},{"name":30,"role":27,"phone":23,"phoneExt":23,"email":23},{"name":88,"role":60,"phone":23,"phoneExt":23,"email":23},"Nicolas PENEL, MD",{"type":90,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[92,94],{"name":93,"class":6},"Canceropôle Nord Ouest",{"name":95,"class":6},"Groupement Interrégional de Recherche Clinique et d'Innovation","100477701","phase-2-assessment-of-compliance-with-monitoring-conducted-by-a-physician-in-person-or-by-a-nurse-in-remote-monitoring-100477701",false,"NCT05500391","Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring","Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring","SUR-CAN","Inclusion Criteria:\n\n* Positive diagnosis (anatomopathology) of tumor within 12 months\n* Patient 18 years of age or older\n* Patient with one of the following conditions:\n\n  1. Desmoid fibromatosis of the abdominal wall operated on or under active surveillance\n  2. Stage I testicular seminoma (whether or not treated with carboplatin AUC7)\n  3. Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy)\n  4. Operated GIST with low risk of relapse\n  5. Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated\n  6. Low-grade glioma, operated\n  7. Low-grade neuroendocrine tumor, treated by surgery alone\n* Patient who has given consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindication to imaging tests required for the surveillance plan\n* No telephone\n* Patient under guardianship or curatorship","ALL","18 Years",{"count":107,"type":108},88,"ESTIMATED","INTERVENTIONAL",[111],"PHASE2","This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (\\\u003C12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).",[114,115,116,117,118,119,120,121,122,123,124,125,126,127],"Stage I Testicular Seminoma","Stage I Testicular Nonseminomatous Germ Cell Tumor","Gastrointestinal Stromal Tumors","Ovarian Germ Cell Tumor","Adenocarcinoma, Clear Cell","Borderline Ovarian Tumor","Sex Cord-Stromal Tumor","Mucinous Adenocarcinoma of Ovary","Carcinoma, Small Cell","Carcinosarcoma, Ovarian","Serous Tumor of Ovary","Glioma","Neuroendocrine Tumors","Aggressive Fibromatosis of Abdominal Wall (Disorder)","2026-03-16",{"date":130,"type":131},"2026-03-18","ACTUAL",{"date":133,"type":131},"2024-02-28",{"date":135,"type":108},"2032-07",{"name":5,"class":6},3]